Skip to main content
Erschienen in: Clinical and Experimental Nephrology 2/2010

01.04.2010 | Original Article

Design and methods of a strategic outcome study for chronic kidney disease: Frontier of Renal Outcome Modifications in Japan

verfasst von: Kunihiro Yamagata, Hirofumi Makino, Tadao Akizawa, Kunitoshi Iseki, Sadayoshi Itoh, Kenjiro Kimura, Daisuke Koya, Ichiei Narita, Tetsuya Mitarai, Masanobu Miyazaki, Yoshiharu Tsubakihara, Tsuyoshi Watanabe, Takashi Wada, Osamu Sakai, Advisory Committee for FROM-J

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The continuous increase in the number of people requiring dialysis is a major clinical and socioeconomical issue in Japan and other countries. This study was designed to encourage chronic kidney disease (CKD) patients to consult a physician, enhance cooperation between nephrologists and general practices, and prevent the progression of kidney disease.

Methods

Subjects comprise CKD patients aged between 40 and 74 years consulting a general physician, and patients in CKD stage 3 with proteinuria and diabetes or hypertension. This trial is a stratified open cluster-randomized study with two intervention groups: group A (weak intervention) and group B (strong intervention). We have recruited 49 local medical associations (clusters) in 15 different prefectures, which were classified into four regions (strata) based on the level of increase rate of dialysis patients. The patients in group A clusters were instructed initially to undergo treatment in accordance with the current CKD treatment guide, whereas patients in group B clusters were not only instructed in the same fashion but also received support from an information technology (IT)-based system designed to help achieve the goals of CKD treatment, consultation support centers, and consultations by dietitians visiting the local general practice offices. We assessed the rates of continued consultation, collaboration between general practitioners and nephrologists, and progression of CKD (as expressed by CKD stage).

Conclusion

Through this study, filling the evidence-practice gap by facilitating effective communication and supporting general physicians and nephrologists, we will establish a CKD care system and decrease the number of advanced-stage CKD patients.
Literatur
1.
Zurück zum Zitat Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007;11:411–41.CrossRefPubMed Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007;11:411–41.CrossRefPubMed
2.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.CrossRefPubMed
3.
Zurück zum Zitat Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–9.CrossRefPubMed Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–9.CrossRefPubMed
4.
Zurück zum Zitat Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease (CKD) in Japanese general population. Clin Exp Nephrol, 2009. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease (CKD) in Japanese general population. Clin Exp Nephrol, 2009.
5.
Zurück zum Zitat Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–36.PubMed Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–36.PubMed
6.
Zurück zum Zitat Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
7.
Zurück zum Zitat Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.PubMed Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.PubMed
8.
Zurück zum Zitat Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005;165:2659–65.CrossRefPubMed Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005;165:2659–65.CrossRefPubMed
9.
Zurück zum Zitat K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:S1–266. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:S1–266.
10.
Zurück zum Zitat Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.CrossRefPubMed
11.
Zurück zum Zitat Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of end-stage renal disease in Japan. Am J Kidney Dis. 2004;43:433–43.CrossRefPubMed Yamagata K, Takahashi H, Suzuki S, Mase K, Hagiwara M, Shimizu Y, et al. Age distribution and yearly changes in the incidence of end-stage renal disease in Japan. Am J Kidney Dis. 2004;43:433–43.CrossRefPubMed
12.
Zurück zum Zitat Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int. 2006;70:187–91.CrossRefPubMed Sorensen VR, Hansen PM, Heaf J, Feldt-Rasmussen B. Stabilized incidence of diabetic patients referred for renal replacement therapy in Denmark. Kidney Int. 2006;70:187–91.CrossRefPubMed
13.
Zurück zum Zitat Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed
14.
Zurück zum Zitat Heagerty A. Optimizing hypertension management in clinical practice. J Hum Hypertens. 2006;20:841–9.CrossRefPubMed Heagerty A. Optimizing hypertension management in clinical practice. J Hum Hypertens. 2006;20:841–9.CrossRefPubMed
15.
Zurück zum Zitat Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, et al. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int. 2003;64:1445–9.CrossRefPubMed Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, et al. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int. 2003;64:1445–9.CrossRefPubMed
16.
Zurück zum Zitat CKD Clinical Practice Guidelines: Japanese Society of Nephrology (written and edited), First edition, Tokyo Igakusha, 2007. CKD Clinical Practice Guidelines: Japanese Society of Nephrology (written and edited), First edition, Tokyo Igakusha, 2007.
17.
Zurück zum Zitat Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA. 2000;284:2622–4.CrossRefPubMed Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA. 2000;284:2622–4.CrossRefPubMed
18.
Zurück zum Zitat Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.CrossRefPubMed Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433–41.CrossRefPubMed
19.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed
20.
Zurück zum Zitat Churchill DN, Blake PG, Jindal KK, Toffelmire EB, Goldstein MB. Clinical practice guidelines for initiation of dialysis. Canadian Society of Nephrology. J Am Soc Nephrol. 1999;10(Suppl 13):S289–91.PubMed Churchill DN, Blake PG, Jindal KK, Toffelmire EB, Goldstein MB. Clinical practice guidelines for initiation of dialysis. Canadian Society of Nephrology. J Am Soc Nephrol. 1999;10(Suppl 13):S289–91.PubMed
21.
Zurück zum Zitat Burden R, Tomson C. Identification, management and referral of adults with chronic kidney disease: concise guidelines. Clin Med. 2005;5:635–42.PubMed Burden R, Tomson C. Identification, management and referral of adults with chronic kidney disease: concise guidelines. Clin Med. 2005;5:635–42.PubMed
22.
Zurück zum Zitat Nicholls K. Prevention of progression of kidney disease: diabetic nephropathy—CARI guidelines. Aust Fam Physician. 2007;36:137–8.PubMed Nicholls K. Prevention of progression of kidney disease: diabetic nephropathy—CARI guidelines. Aust Fam Physician. 2007;36:137–8.PubMed
23.
Zurück zum Zitat IV. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001; 37:S182–238. IV. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001; 37:S182–238.
24.
Zurück zum Zitat Neumann ME. Results in KEEP’s first report show progress in early identification of CKD patients. Nephrol News Issues. 2003;17:84–7.PubMed Neumann ME. Results in KEEP’s first report show progress in early identification of CKD patients. Nephrol News Issues. 2003;17:84–7.PubMed
25.
Zurück zum Zitat Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. Nephron. 2002;91:34–42.CrossRefPubMed Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. Nephron. 2002;91:34–42.CrossRefPubMed
26.
Zurück zum Zitat Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al. Factors affecting renal function in 119 985 adults over three years. QJM. 2001;94:541–50.CrossRefPubMed Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al. Factors affecting renal function in 119 985 adults over three years. QJM. 2001;94:541–50.CrossRefPubMed
27.
Zurück zum Zitat Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48:383–91.CrossRefPubMed Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis. 2006;48:383–91.CrossRefPubMed
28.
Zurück zum Zitat Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients—absence of evidence or evidence of absence?. Clin J Am Soc Nephrol. 2008;3:226–36.CrossRefPubMed Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients—absence of evidence or evidence of absence?. Clin J Am Soc Nephrol. 2008;3:226–36.CrossRefPubMed
29.
Zurück zum Zitat The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977–86. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977–86.
30.
Zurück zum Zitat Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.CrossRefPubMed
31.
Zurück zum Zitat Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–61.PubMed Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646–61.PubMed
32.
Zurück zum Zitat Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–91.PubMed Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–91.PubMed
33.
Zurück zum Zitat Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed
34.
Zurück zum Zitat Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.CrossRefPubMed Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–45.CrossRefPubMed
35.
Zurück zum Zitat Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34:809–17.CrossRefPubMed Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis. 1999;34:809–17.CrossRefPubMed
36.
Zurück zum Zitat Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed
37.
Zurück zum Zitat Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.CrossRefPubMed Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetzels JF, De Zeeuw D, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol. 2006;17:2582–90.CrossRefPubMed
Metadaten
Titel
Design and methods of a strategic outcome study for chronic kidney disease: Frontier of Renal Outcome Modifications in Japan
verfasst von
Kunihiro Yamagata
Hirofumi Makino
Tadao Akizawa
Kunitoshi Iseki
Sadayoshi Itoh
Kenjiro Kimura
Daisuke Koya
Ichiei Narita
Tetsuya Mitarai
Masanobu Miyazaki
Yoshiharu Tsubakihara
Tsuyoshi Watanabe
Takashi Wada
Osamu Sakai
Advisory Committee for FROM-J
Publikationsdatum
01.04.2010
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 2/2010
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0249-4

Weitere Artikel der Ausgabe 2/2010

Clinical and Experimental Nephrology 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.